In the first episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, discusses InMed’s biosynthesis platform and its pipeline of cannabinoids with Eric A. Adams, InMed’s CEO, and Alexandra Mancini, senior VP of clinical and regulatory affairs. The discussion also includes the recent FDA public hearing on cannabidiol (CBD) and its implications for the sector.
Current research into the potential therapeutic effects of cannabinol (CBN)
How do cannabinoids interact with the human body? There has been a significant growth in interest and research into the potential therapeutic properties of cannabinoids.
April 8, 2021
